Chromos Molecular Systems Overview

  • Year Founded
  • 1995

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

Chromos Molecular Systems General Information

Description

Developer of artificial chromosome technology for use in biopharmaceutical production. The company focuses on the development of proprietary artificial chromosome expression system technology that is used to engineer production quality cell lines to manufacture biopharmaceutical products, including monoclonal antibodies and the development of human therapeutic products.

Contact Information

Website
www.chromos.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 2020 1055 West Hastings Street
  • Vancouver, British Columbia
  • Canada
Primary Industry
Media and Information Services (B2B)
Acquirer
Calyx Ventures
Vertical(s)
Life Sciences
Corporate Office
  • 2020 1055 West Hastings Street
  • Vancouver, British Columbia
  • Canada

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Chromos Molecular Systems Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 22-Oct-2008 Completed Generating Revenue
3. IPO 10-Jul-2000 Completed Generating Revenue
2. Early Stage VC 27-Apr-1999 $8.05M $15.9M Completed Startup
1. Early Stage VC 18-Jul-1997 $7.84M $7.84M Completed Product Development
To view Chromos Molecular Systems’s complete valuation and funding history, request access »

Chromos Molecular Systems Patents

  • 37

    Total Documents Applications and Grants

  • Total Patents Families

  • 3

    Granted

  • 1

    Pending

  • Expiring in next 12 mo

Chromos Molecular Systems Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20080132949-A1 Apparatus and method for anterior intervertebral spinal fixation and fusion Active 29-Dec-2005
US-7594932-B2 Apparatus for anterior intervertebral spinal fixation and fusion Active 29-Dec-2005
WO-2007056858-A1 Anti-alpha2 integrin antibodies and their uses Inactive 18-Nov-2005
US-20030224522-A1 Designed for introduction of large nucleic acid molecules, including artificial chromosomes, into cells Inactive 01-May-2002
AU-2003221584-A1 Methods for delivering nucleic acid molecules into cells and assessment thereof Inactive 01-May-2002 C12N15/88
To view Chromos Molecular Systems’s complete patent history, request access »

Chromos Molecular Systems Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
BDC Capital Growth/Expansion Minority
GeneChem Venture Capital Minority
GrowthWorks Venture Capital Minority
Inex Pharmaceuticals Corporation Minority
RBC Venture Partners Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

Chromos Molecular Systems Acquisitions (1)

Chromos Molecular Systems’s most recent deal was a Merger/Acquisition with Targeted Molecules for . The deal was made on 25-May-2005.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Targeted Molecules 25-May-2005 Merger/Acquisition Drug Discovery
To view Chromos Molecular Systems’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

Chromos Molecular Systems FAQs

  • When was Chromos Molecular Systems founded?

    Chromos Molecular Systems was founded in 1995.

  • Where is Chromos Molecular Systems headquartered?

    Chromos Molecular Systems is headquartered in Vancouver, Canada.

  • What industry is Chromos Molecular Systems in?

    Chromos Molecular Systems’s primary industry is Media and Information Services (B2B).

  • Is Chromos Molecular Systems a private or public company?

    Chromos Molecular Systems is a Private company.

  • What is Chromos Molecular Systems’s current revenue?

    The current revenue for Chromos Molecular Systems is .

  • How much funding has Chromos Molecular Systems raised over time?

    Chromos Molecular Systems has raised $36.2M.

  • Who are Chromos Molecular Systems’s investors?

    BDC Capital, GeneChem, GrowthWorks, Inex Pharmaceuticals, and RBC Venture Partners are 5 of 8 investors who have invested in Chromos Molecular Systems.

  • When was Chromos Molecular Systems acquired?

    Chromos Molecular Systems was acquired on 22-Oct-2008.

  • Who acquired Chromos Molecular Systems?

    Chromos Molecular Systems was acquired by Calyx Ventures.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process